KOLIBRI
Paris · Founded 2021
About KOLIBRI
In the biotech space, cell and gene therapy and clean meat are two of the most promising industries. Yet both are facing the same issue: large-scale cell culture remains the blocking point to scale up and make both cell and gene therapies and clean meat accessible and affordable. To that end, Kolibri is building a proprietary cell-engineering platform, combining cutting edge techniques in acoustics and biology, allowing for a 90x higher yield while decreasing production costs up to 50x.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $3.1M
- Funding stage: Seed
- Last round: Seed (Mar 2023)
- Website: https://kolibrilab.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science, Manufacturing
Social Profiles
Canonical: https://fsome.com/organization/kolibri-87009 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.